Open Actively Recruiting

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

About

Brief Summary

This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.

This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase I

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
110 Years

Abbreviated Inclusion Criteria:

  • Age 18 years or older, is willing and able to provide informed consent
  • Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
  • Life expectancy > 12 weeks
  • ECOG performance status of 0-1

Abbreviated Exclusion Criteria:

  • History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
  • Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
  • Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
  • History of severe autoimmune disease
  • Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
20-000559
Category
Hematology-Oncology
Oncology
Contact
Lisa Yonemoto
Location
  • UCLA Santa Monica
For Providers
NCT No.
NCT04306900
For detailed technical eligibility, visit ClinicalTrials.gov.